Company search
Overview
Performance
Portfolio
Dividends
Charges
Gearing
Research
Announcements
Management
Documents
Invest
Portfolio yield
Data as at : 30/11/2025
| % |
|---|
| 0.4 |
Please note that the above fields are displayed for companies that have reported this data to the AIC. Where data is reported, it may be subject to valuation lags.
Top holdings
Data as at : 31/10/2025
| Investment | % of total assets |
|---|---|
| Eli Lilly and Co | 9.7 |
| AstraZeneca PLC | 5.2 |
| Thermo Fisher Scientific Inc | 4.7 |
| CVS Health Corp | 3.8 |
| Boston Scientific Corp | 3.6 |
| Teva Pharmaceutical Industries Ltd ADR | 3.6 |
| UCB SA | 3.4 |
| Fresenius SE & Co KGaA | 3.3 |
| Insulet Corp | 3.2 |
| West Pharmaceutical Services Inc | 3.1 |
Geographic breakdown
Data as at : 30/11/2025
| Country | % of total assets |
|---|---|
| USA | 44.0 |
| UK | 14.0 |
| Canada | 4.0 |
| Germany | 4.0 |
| Italy | 4.0 |
| India | 3.0 |
| Ireland | 3.0 |
| Japan | 3.0 |
| Sweden | 3.0 |
| Austria | 2.0 |
| Greece | 2.0 |
| Hong Kong | 2.0 |
| Spain | 2.0 |
| China | 1.0 |
| France | 1.0 |
| Indonesia | 1.0 |
| Israel | 1.0 |
| South Korea | 1.0 |
Depending on the nature of the underlying asset classes, geographic breakdowns may not always add up to 100%.
Industry breakdown
Data as at : 31/10/2025
| Industry | % of total assets |
|---|---|
| Healthcare | 98.8 |
| Cash Equivalents | 1.2 |
Scroll
Asset breakdown
Data as at : 31/10/2025
| Asset | % of total assets |
|---|---|
| Stock | 98.8 |
| Cash/Cash equivalents | 1.2 |
Detailed asset breakdown
Data as at : 31/10/2025
| Asset | % of total assets |
|---|---|
| North America - stock | 57.2 |
| Europe - Large-cap stock | 14.2 |
| Europe - Mid-cap stock | 5.2 |
| UK - Large core/growth stock | 5.2 |
| Asia (excl Japan) - stock | 4.9 |
| Other - stock | 4.8 |
| Emerging markets - stock | 3.6 |
| Europe - Small-cap stock | 2.9 |
| Cash | 1.2 |
Data provided by Morningstar.
Company documents provided by FE fundinfo.
